ClinicalTrials.govpublic full text
Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC
triple negative breast cancer, pi3ca/akt1/pten genetic alterations, newly diagnosed tnbc, ipatasertib, atezolizumab, neo-adjuvant, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 888572
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.